CompletedPhase 2NCT01413100
Scleroderma Treatment With Autologous Transplant (STAT) Study
Studying Cerebrotendinous xanthomatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fred Hutchinson Cancer Center
- Principal Investigator
- Leona HolmbergFred Hutch/University of Washington Cancer Consortium
- Intervention
- Anti-Thymocyte Globulin(biological)
- Enrollment
- 21 enrolled
- Eligibility
- 70 years · All sexes
- Timeline
- 2011 – 2024
Study locations (12)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
- University of Colorado, Denver, Colorado, United States
- Colorado Blood Cancer Institute, Denver, Colorado, United States
- Boston Medical Center, Boston, Massachusetts, United States
- Boston University School of Medicine, Boston, Massachusetts, United States
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
- Duke University Medical Center, Durham, North Carolina, United States
- M D Anderson Cancer Center, Houston, Texas, United States
- The University of Texas Health Science Center, Houston, Houston, Texas, United States
- Seattle Children's Hospital, Seattle, Washington, United States
- Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01413100 on ClinicalTrials.govOther trials for Cerebrotendinous xanthomatosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07510802Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBCBeijing Biotech
- RECRUITINGPHASE1NCT07162038Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell TransplantationNational Cancer Institute (NCI)
- RECRUITINGNANCT06790225Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)Esbjerg Hospital - University Hospital of Southern Denmark
- RECRUITINGPHASE2NCT05909059CAR T-cell Therapy in Patients With Renal DysfunctionNorthside Hospital, Inc.
- RECRUITINGPHASE2NCT06042569Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY TrialCity of Hope Medical Center
- RECRUITINGPHASE1, PHASE2NCT06594640R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT05748197A Study of ADCLEC.syn1 in People With Acute Myeloid LeukemiaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT05883852EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast CancerFudan University